|
Patent landscape, scope, and claims: |
United States Drug Patent 7,252,839: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 7,252,839, titled "Substituted triazolopyrimidine derivatives," was granted on August 7, 2007, to Bayer HealthCare AG. The patent covers a class of chemical compounds and their use in treating various medical conditions. The primary focus of the patent is on novel triazolopyrimidine derivatives, including specific exemplary compounds, and their therapeutic applications, particularly in the treatment of diseases associated with aberrant kinase activity. The patent landscape surrounding this technology is competitive, with numerous entities holding patents related to kinase inhibitors and their therapeutic uses. Understanding the breadth of claims within U.S. Patent 7,252,839 is critical for assessing potential infringement risks and identifying opportunities for new drug development.
What is the core innovation protected by U.S. Patent 7,252,839?
The core innovation protected by U.S. Patent 7,252,839 is a new class of chemical compounds, specifically substituted triazolopyrimidine derivatives. These compounds are designed to act as inhibitors of certain protein kinases, enzymes that play a crucial role in cellular signaling pathways. Dysregulation of kinase activity is implicated in a range of diseases, including cancer, inflammatory disorders, and autoimmune diseases. The patent claims these novel compounds and their pharmaceutical compositions for use in treating such conditions.
The invention also addresses the synthesis and formulation of these active pharmaceutical ingredients. The patent provides specific examples of synthesized compounds and details methods for their preparation. This granular information is essential for defining the scope of protection.
What are the key claims within U.S. Patent 7,252,839?
U.S. Patent 7,252,839 contains several independent and dependent claims that define the scope of the invention. These claims can be broadly categorized as follows:
Independent Claims
- Claim 1: This is a foundational independent claim that defines a general class of substituted triazolopyrimidine compounds. It specifies a core triazolopyrimidine ring system with various substituents at defined positions (e.g., positions 1, 2, 3, 5, 6, and 7). The claim outlines a broad chemical structure with variable R-groups, each defined by a range of possible chemical moieties. For example, R¹ could be hydrogen or a halogen, while R² could be a substituted amino group, an alkyl group, or an aryl group. The precise definitions of these R-groups are critical to the scope of the claim. The claim further specifies that the compound is "free of a [specific] phenyl ring or a [specific] pyrazole ring system." This exclusion is significant as it carves out specific structures that might otherwise fall under a broader definition.
- Claim 11: This independent claim focuses on pharmaceutical compositions. It claims a composition comprising one or more of the compounds described in Claim 1 (or pharmaceutically acceptable salts, solvates, or polymorphs thereof) and a pharmaceutically acceptable carrier or diluent. This claim protects the formulation of the active compounds into a usable drug product.
Dependent Claims
A significant portion of the patent’s claims are dependent, narrowing the scope of the independent claims by providing more specific structural definitions or therapeutic uses. Examples of dependent claims include:
- Claims that specify particular substituents for the R-groups defined in Claim 1. For instance, a dependent claim might specify that R² is a "4-morpholinyl group" or a "N-(methyl)-N-(ethyl)amino group."
- Claims that define specific salts, solvates, or crystalline forms of the claimed compounds.
- Claims that specify particular medical conditions for which the compounds are to be used. These often relate to diseases mediated by specific kinase pathways, such as JAK kinases or related signaling molecules. Examples of such conditions mentioned in the patent’s written description and often reflected in dependent claims include inflammatory diseases, autoimmune diseases, and proliferative disorders.
- Claims that specify particular dosage ranges or administration routes for the pharmaceutical compositions.
The precise wording and chemical structures defined within these claims are paramount for determining the patent's enforceability and the extent of its protection. For instance, the exclusion of certain phenyl or pyrazole rings in Claim 1 is a deliberate limitation to avoid prior art.
What is the technological scope of U.S. Patent 7,252,839?
The technological scope of U.S. Patent 7,252,839 encompasses:
- Novel Chemical Entities: The patent protects a specific structural class of organic molecules, the substituted triazolopyrimidines. This includes not only the general genus but also numerous specific species within that genus.
- Pharmaceutical Compositions: It covers formulations of these compounds suitable for medicinal use, including mixtures with excipients, carriers, and diluents.
- Methods of Treatment: The patent claims the use of these compounds and compositions for treating diseases. The specific diseases targeted are those associated with aberrant kinase activity, which are further detailed in the patent’s written description and dependent claims. This includes conditions like rheumatoid arthritis, psoriasis, inflammatory bowel disease, and certain types of cancer.
- Synthesis and Manufacturing: While not always the primary focus of patent claims, the underlying synthesis pathways and potential manufacturing considerations for these compounds are part of the technological disclosure and can influence process patenting.
The invention focuses on small molecule inhibitors. These are chemically synthesized compounds, as opposed to biological or protein-based therapies. The specific kinase targets are not always explicitly listed in the independent claims but are inferable from the patent’s examples and background information. The core innovation lies in identifying and claiming a novel chemical scaffold with potent biological activity against key therapeutic targets.
Who are the key players and what is the patent landscape surrounding U.S. Patent 7,252,839?
The patent landscape for kinase inhibitors, including those related to U.S. Patent 7,252,839, is highly competitive. Key players typically include large pharmaceutical companies with significant R&D investments in oncology, immunology, and inflammation.
Assignee: The assignee of U.S. Patent 7,252,839 is Bayer HealthCare AG. This indicates Bayer’s ownership and control over the intellectual property associated with these specific triazolopyrimidine derivatives.
Competitor Landscape: The broader landscape involves numerous companies developing kinase inhibitors. Identifying direct competitors requires analyzing patents claiming similar chemical structures or targeting the same kinase pathways.
Companies active in this space include, but are not limited to:
- Pfizer Inc.: Known for developing numerous kinase inhibitors across various therapeutic areas.
- Novartis AG: Has a strong portfolio in oncology and immunology, often involving kinase inhibition.
- Gilead Sciences, Inc.: Active in developing novel therapeutics, including kinase inhibitors for inflammatory diseases and oncology.
- Bristol-Myers Squibb Company: A major player in cancer immunotherapy and targeted therapies.
- AbbVie Inc.: Has significant R&D in autoimmune and inflammatory diseases, often utilizing small molecule inhibitors.
- Eli Lilly and Company: Active in oncology and immunology with a pipeline of kinase inhibitors.
Patent Analysis: A detailed patent landscape analysis would involve:
- Identifying patents citing U.S. Patent 7,252,839: These are patents that build upon or reference the technology disclosed in this patent, indicating potential areas of innovation and future development.
- Identifying patents claiming similar chemical structures: This involves searching patent databases for compounds with similar core structures, even if they have different substituents or are claimed for different uses. Chemical structure searching tools are essential for this.
- Identifying patents targeting the same biological pathways: Even if the chemical structures differ, patents claiming inhibitors of the same kinases or signaling pathways are considered competitors in the therapeutic space.
- Monitoring patent filings by key competitors: Tracking new patent applications from major pharmaceutical companies in the kinase inhibitor space can reveal emerging threats and opportunities.
The complexity of kinase inhibition means that multiple companies may hold patents on different inhibitors of the same kinase or on different uses of related compounds. This can lead to intricate licensing negotiations and potential litigation.
What are the implications of U.S. Patent 7,252,839 for R&D and investment decisions?
The existence and scope of U.S. Patent 7,252,839 have several critical implications for R&D and investment decisions:
For R&D:
- Freedom to Operate (FTO): Companies developing new kinase inhibitors, particularly those with triazolopyrimidine scaffolds or targeting similar pathways, must conduct thorough FTO analyses. U.S. Patent 7,252,839 may block the development and commercialization of compounds that fall within its claims.
- Designing Around: Innovators may need to design new chemical entities that fall outside the specific structural claims of this patent. This could involve altering the core scaffold, modifying substituents in a way that avoids infringing claims, or targeting different kinases or pathways.
- Identifying White Space: Analyzing the limitations of this patent and the broader patent landscape can reveal unexplored areas of chemical space or therapeutic targets that are not yet heavily patented.
- Potential for Licensing: If a company’s R&D efforts align with the technology disclosed in this patent, it may present an opportunity to license the patent from Bayer HealthCare AG.
For Investment:
- Risk Assessment: Investors must assess the patent risk associated with companies developing kinase inhibitors. The presence of patents like U.S. Patent 7,252,839 can significantly impact a company’s competitive advantage and market exclusivity.
- Valuation: The strength and breadth of a company’s patent portfolio, including its ability to navigate or challenge existing patents, are crucial factors in valuation. A strong patent position can justify higher valuations.
- Market Exclusivity: Patents grant market exclusivity for a limited period. Investors need to understand the expiration dates of key patents, such as U.S. Patent 7,252,839, to forecast future market competition and potential generic entry.
- Litigation Risk: Investments in companies operating in crowded patent spaces carry inherent litigation risk. Competitors may challenge the validity of existing patents or claim infringement, leading to costly legal battles.
The specific therapeutic indications claimed and the biological targets indicated by the patent are crucial for understanding its commercial relevance and the competitive landscape of those specific disease areas. Bayer’s development of compounds like Elbasvir, although unrelated to this specific patent's core structure, demonstrates their activity in drug development. However, the commercial success of any drug derived from U.S. Patent 7,252,839 would depend on extensive clinical trials, regulatory approval, and market adoption, all of which are influenced by the patent's lifespan and enforceability.
Key Takeaways
- U.S. Patent 7,252,839 protects a class of substituted triazolopyrimidine derivatives and their use as kinase inhibitors for treating various diseases.
- The patent’s claims are specific regarding the chemical structure of the compounds and their therapeutic applications, with exclusions for certain ring systems.
- The patent landscape for kinase inhibitors is crowded, with major pharmaceutical companies actively filing and holding related patents.
- Companies and investors must carefully assess freedom to operate, potential infringement, and white space opportunities in this technologically dynamic field.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 7,252,839?
U.S. Patent 7,252,839 was granted on August 7, 2007. The standard term for U.S. utility patents is 20 years from the date of application filing. Without the application filing date, the precise expiration date cannot be determined, but it would likely be in the early to mid-2020s, subject to any patent term adjustments or extensions.
-
Can compounds covered by U.S. Patent 7,252,839 still be manufactured or sold if the patent has expired?
Yes, once a patent expires, the technology it covers enters the public domain. This means that other entities can manufacture, use, sell, or import the patented compounds or use the patented methods without infringing the expired patent, provided no other patents are in force covering those activities.
-
Does U.S. Patent 7,252,839 claim specific drugs that are currently on the market?
A thorough search of commercial drug databases and patent litigation records would be required to definitively link specific marketed drugs to this patent. The patent claims a genus of compounds; individual drugs are specific species within that genus. It is possible that drugs developed by Bayer HealthCare AG or its licensees fall within the scope of this patent.
-
What does it mean to have a "pharmaceutically acceptable carrier or diluent" in a patent claim?
A pharmaceutically acceptable carrier or diluent refers to inactive ingredients that are mixed with the active pharmaceutical ingredient (API) to create a finished drug product. These inactive ingredients are chosen for their safety, stability, and ability to facilitate the administration and absorption of the API. Examples include water, saline, starch, cellulose, and various binders or coatings.
-
How can a competitor determine if their compound infringes on U.S. Patent 7,252,839?
Infringement analysis involves a detailed comparison of the competitor's compound structure and its intended use against the specific language of each claim in U.S. Patent 7,252,839. This requires expertise in patent law and chemistry, often involving claim construction and a review of prosecution history. A formal opinion of non-infringement or a freedom-to-operate opinion from a qualified patent attorney is recommended.
Citations
[1] Bayer HealthCare AG. (2007). Substituted triazolopyrimidine derivatives. U.S. Patent 7,252,839. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
